Transferring to insulin detemir from NPH insulin or insulin glargine in type 2 diabetes patients on basal-only therapy with oral antidiabetic drugs improves glycaemic control and reduces weight gain and risk of hypoglycaemia: 14-week follow-up data from PREDICTIVE™

Diabetes, Obesity and Metabolism

Volumn 10, Issue 1, 2008, Pages 75-81

  Dornhorst, A ^a   Luddeke H J ^b   Koenen, C ^c   Merilainen M ^c   King, A ^d   Robinson, A ^e   Sreenan, S ^f  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b Praxis Lüddeke Trauner   (Germany)

^c NOVO NORDISK A S   (Denmark)

^d Diabetes Care Center   (United States)

^e ROYAL BOLTON HOSPITAL   (United Kingdom)

^f Stroke and Hypertension Unit   (Ireland)

Author keywords

Body weight; Hypoglycaemia; Insulin analogue; Insulin detemir; Type 2 diabetes

Indexed keywords

HEMOGLOBIN A1C; INSULIN DETEMIR; INSULIN GLARGINE; ISOPHANE INSULIN; ORAL ANTIDIABETIC AGENT;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; RISK ASSESSMENT; RISK REDUCTION; SIDE EFFECT; WEIGHT GAIN;

EID: 37349093469     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/j.1463-1326.2007.00816.x     Document Type: Article

References (18)

1. Maedler K, Donath MY. Beta-cells in type 2 diabetes: A loss of function and mass. Horm Res 2004; 62 (Suppl. 3): 67-73.
2. Wright A, Burden ACF, Paisey RB, Cull CA, Holman RR, U.K. Prospective Diabetes Study Group. Sulfonylurea inadequacy: Efficacy of addition of insulin over 6 years in patients with type 2 diabetes in the U.K. Prospective Diabetes Study (UKPDS 57). Diabetes Care 2002; 25: 330-336.
3. Hirsch IB, Bergenstal RM, Parkin CG, Wright E, Buse JB. A real-world approach to insulin therapy in primary care practice. Clin Diabetes 2005; 23: 78-86.
4. Polonsky KS, Given BD, Hirsch LJ et al. Abnormal patterns of insulin secretion in non-insulin dependent diabetes mellitus. N Engl J Med 1988; 318: 1231-1239.
5. UK Prospective Diabetes Study Group. Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-853.
6. Polonsky WH, Anderson BJ, Lohrer PA, Aponte JE, Jacobson AM, Cole CF. Insulin omission in women with IDDM. Diabetes Care 1994; 17: 1178-1185.
7. Davis S, Alonso MD. Hypoglycemia as a barrier to glycemic control. J Diabetes Complications 2004; 18: 60-68.
8. Polonsky WH, Fisher L, Guzman S, Villa-Caballero L, Edelman SV. Psychological insulin resistance in patients with type 2 diabetes. Diabetes Care 2005; 28: 2543-2545.
9. Raslova K, Bogoev M, Raz I, Leth G, Gall MA, Hancu M. Insulin detemir and insulin aspart: A promising basal-bolus regimen for type 2 diabetes. Diabetes Res Clin Pract 2004; 66: 193-201.
10. Haak T, Tiengo A, Draeger E, Suntum M, Waldhausl W. Lower within-subject variability of fasting blood glucose and reduced weight gain with insulin detemir compared to NPH insulin in patients with type 2 diabetes. Diabetes Obes Metab 2005; 7: 56-64.
11. Hermansen K, Davies M, Derezinski T, Martinez Ravn G, Clauson P, Home P. A 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naive people with type 2 diabetes. Diabetes Care 2006; 29: 1269-1274.
12. Riddle MC, Rosenstock J, Gerich J, Insulin glargine 4002 Study Investigators. The treat-to-target trial: Randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care 2003; 26: 3080-3086.
13. Janka HU, Plewe G, Riddle MC, Kliebe-Frisch C, Schweitzer MA, Yki-Jarvinen H. Comparison of basal insulin added to oral agents versus twice-daily premixed insulin as initial insulin therapy for type 2 diabetes. Diabetes Care 2005; 28: 254-259.
14. Rosenstock J, Dailey G, Massi-Benedetti M, Fritsche A, Lin Z, Salzman A. Reduced hypoglycemia risk with insulin glargine: A meta-analysis comparing insulin glargine with human NPH insulin in type 2 diabetes. Diabetes Care 2005; 28: 950-955.
15. Rosenstock J, Davies M, Home PD et al. Insulin detemir added to oral antidiabetic drugs in type 2 diabetes provides glycemic control comparable to insulin glargine with less weight gain. Diabetes 2006; 55: A132.
16. Lüddeke H-J, Philotheou A, Horn-Rosenberg K, Nielsen M, Sreenan S, Dornhorst A. PREDICTIVE™: A global, prospective, observational study to evaluate insulin detemir treatment in type 1 and type 2 diabetes -14-week follow-up data. Diabet Med 2006; 23: P380 (Abstract).
17. Lüddeke H-J, Sreenan S, Aczel S et al. PREDICTIVE™: A global, prospective, observational study to evaluate insulin detemir treatment in type 1 and 2 diabetes -baseline characteristics and predictors of hypoglycaemia from the European cohort. Diabetes Obes Metab 2007; 9: 428-434.
18. 1c standardisation destination - global IFCC standardisation. How, why, where and when - a tortuous pathway from kit manufacturers, via inter-laboratory lyophilized and whole blood comparisons to designated national comparison schemes. Clin Biochem Rev 2005; 26: 5-19.